The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy
Abstract
BACKGROUND: In patients with venous thromboembolism (VTE), identifying clinical risk factors for recurrence during the initial 3 months of anticoagulant therapy and knowledge of the time course of recurrence may help clinicians decide about the frequency of clinical surveillance and the appropriateness of outpatient treatment. METHODS: Analysis of a randomized controlled trial database involving 1021 patients with VTE (750 with deep vein thrombosis [DVT] and 271 with pulmonary embolism [PE]) who were followed up for 3 months after the start of anticoagulant therapy. All patients received initial treatment with unfractionated heparin or a low-molecular-weight heparin (reviparin) and a coumarin derivative starting the first or second day of treatment, with a target international normalized ratio of 2.0 to 3.0. RESULTS: Four independent clinical risk factors for recurrent VTE were identified: (1) cancer (odds ratio [OR], 2.72; 95% confidence interval [CI], 1. 39-5.32), (2) chronic cardiovascular disease (OR, 2.27; 95% CI, 1. 08-4.97), (3) chronic respiratory disease (OR, 1.91; 95% CI, 0.85-4. 26), and (4) other clinically significant medical disease (OR, 1.79; 95% CI, 1.00-3.21). Older age was associated with a decreased risk for recurrent VTE (OR, 0.76; 95% CI, 0.64-0.92). Previous VTE, sex, and idiopathic VTE were not risk factors for recurrence. In patients with DVT or PE, there was no significant difference in the rates of recurrent nonfatal VTE (4.8% vs 4.1%; P =.62), major bleeding (2.9% vs 2.2%; P =.53), and non-VTE death (6.4% vs 7.8%; P =.45), but recurrent fatal PE was more frequent in patients with PE than DVT (2. 2% vs 0%; P<.01). There was a clustering of recurrent VTE episodes during the initial 2 to 3 weeks after the start of treatment. CONCLUSIONS: During the initial 3 months of anticoagulant therapy, recurrent VTE is more likely to occur in patients with cancer, chronic cardiovascular disease, chronic respiratory disease, or other clinically significant medical disease. Patients with PE are as likely to develop recurrent VTE as those with DVT; however, recurrence is more likely to be fatal in patients who initially present with PE. Arch Intern Med. 2000;160:3431-3436.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Self-citationHemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citationSchulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
HULL, R. D., HIRSH, J., CARTER, C. J., JAY, R. M., DODD, P. E., OCKELFORD, P. A., COATES, G., GILL, G. J., TURPIE, A. G., DOYLE, D. J., et al. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-891 · Cited by 645
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Self-citationPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Self-citationIncidence and mortality of venous thrombosis: a population‐based study
NÆSS, I. A., CHRISTIANSEN, S. C., ROMUNDSTAD, P., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTRØM, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02450.x · Cited by 1,413
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,093
Palareti, G., Legnani, C., Cosmi, B., Antonucci, E., Erba, N., Poli, D., Testa, S., Tosetto, A., & the DULCIS (D‐dimer‐ULtrasonography in Combination Italian Study) Investigators (See Appendix) (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12426 · Cited by 902
The Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830
Self-citationLinkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Self-citationBritish Thoracic Society guidelines for the management of suspected acute pulmonary embolism
(2003) · Thorax · doi:10.1136/thorax.58.6.470 · Cited by 686
Laporte, S., Mismetti, P., Décousus, H., Uresandi, F., Otero, R., Lobo, J. L., Monreal, M., & the RIETE Investigators (2008) · Circulation · doi:10.1161/circulationaha.107.726232 · Cited by 671
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
Campbell, I. A., Fennerty, A., & Miller, A. C. (2005) · PULMONOLOGIYA · doi:10.18093/0869-0189-2005-0-4-19-39 · Cited by 458
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Murad, M. H., Arcelus, J. I., Dager, W. E., Dunn, A. S., Fargo, R. A., Levy, J. H., Samama, C. M., Shah, S. H., et al. (2022) · CHEST · doi:10.1016/j.chest.2022.07.025 · Cited by 450
Self-citationvan Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub2 · Cited by 433
Self-citationCook, D., Crowther, M., Meade, M., Rabbat, C., Griffith, L., Schiff, D., Geerts, W., & Guyatt, G. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000171207.95319.b2 · Cited by 430
Self-citationKaufman, J. A., Kinney, T. B., Streiff, M. B., Sing, R. F., Proctor, M. C., Becker, D., Cipolle, M., Comerota, A. J., Millward, S. F., Rogers, F. B., et al. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000203418-39769.0d · Cited by 413
Erkens, P. M., & Prins, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub3 · Cited by 301
Self-citationOutcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., & Rivera, E. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1653 · Cited by 269
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Gage, B. F., & Lesko, L. J. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0104-y · Cited by 254
Gallego, P., Roldan, V., Marín, F., Romera, M., Valdés, M., Vicente, V., & Lip, G. Y. H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0556 · Cited by 187
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30191-1 · Cited by 84
Metadata
- Authors
- Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-12-11
- Volume
- 160
- Issue
- 22
- Pages
- 3431
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2158662386
- Cited by
- 269
- References
- 40
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.